Banan Rouzbeh, Abbetmeier-Basse Merle, Hong Bujung, Dumitru Claudia A, Sahm Felix, Nakamura Makoto, Krauss Joachim K, Hartmann Christian
Department of Neuropathology, Institute of Pathology, Hannover Medical School, Hannover, Germany.
Department of Neurosurgery, Hannover Medical School, Hannover, Germany.
Neuropathol Appl Neurobiol. 2021 Oct;47(6):724-735. doi: 10.1111/nan.12700. Epub 2021 Feb 25.
Brain invasion (BI) was firstly defined as a single criterion of atypia in otherwise benign meningiomas in the revised fourth edition of 2016 WHO classification of brain tumours after being previously inconsistently addressed. However, recent studies have raised doubts about the prognostic significance of BI in otherwise benign meningiomas. In our study, we investigate the reproducibility of such a prognostic effect.
We identified two cohorts one consisting of 483 patients with meningioma WHO grade I (M°I) or atypical meningioma WHO grade II (M°II) from Hannover Medical School and the other including atypical meningiomas defined according to the classical WHO criteria (M°IIb) from the University Hospital Heidelberg. Follow-up data with a median observation time of 38.2 months were available from 308 cases. These included 243 M°I and 65 M°II patients with the latter group consisting of 25 patients with otherwise benign meningiomas with BI (M°IIa) and 40 with M°IIb.
A significant difference of progression-free interval (PFI) was found between patients with M°I and M°II, M°I and M°IIa and those with M°I and M°IIb of both cohorts and each separately. However, PFI of M°IIa and M°IIb patients showed no significant difference. In the multivariate regression analysis adjusted for M°I/M°IIa versus M°IIb, sex, age, extent of resection and tumour location, BI exhibited the strongest risk of relapse (Hazard ratio: 4.95) serving as an independent predictor of PFI (p = 0.002).
Our results clearly support the definition of BI as a single criterion of atypia in WHO classification of 2016.
脑侵犯(BI)在2016年世界卫生组织(WHO)脑肿瘤分类修订第四版中首次被定义为其他方面为良性的脑膜瘤非典型性的单一标准,此前该问题一直未得到一致解决。然而,最近的研究对BI在其他方面为良性的脑膜瘤中的预后意义提出了质疑。在我们的研究中,我们调查了这种预后效应的可重复性。
我们确定了两个队列,一个队列由来自汉诺威医学院的483例WHO I级脑膜瘤(M°I)或WHO II级非典型脑膜瘤(M°II)患者组成,另一个队列包括来自海德堡大学医院根据WHO经典标准定义的非典型脑膜瘤(M°IIb)。308例患者可获得中位观察时间为38.2个月的随访数据。其中包括243例M°I患者和65例M°II患者,后者包括25例其他方面为良性但有脑侵犯的脑膜瘤患者(M°IIa)和40例M°IIb患者。
两个队列以及每个队列中,M°I与M°II、M°I与M°IIa以及M°I与M°IIb患者之间的无进展生存期(PFI)存在显著差异。然而,M°IIa和M°IIb患者的PFI无显著差异。在针对M°I/M°IIa与M°IIb、性别、年龄、切除范围和肿瘤位置进行调整的多变量回归分析中,脑侵犯表现出最强的复发风险(风险比:4.95),是PFI的独立预测因子(p = 0.002)。
我们的结果明确支持将脑侵犯定义为2016年WHO分类中非典型性的单一标准。